SEC Filings

Form 10-Q
PROTAGONIST THERAPEUTICS, INC filed this Form 10-Q on 08/07/2018
Document Outline
Entire Document (4356.3 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - PROTAGONIST THERAPEUTICS, INC.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - PROTAGONIST THERAPEUTICS, INC.
Page 5 - PROTAGONIST THERAPEUTICS, INC.
Page 6 - PROTAGONIST THERAPEUTICS, INC.
Page 7 - PROTAGONIST THERAPEUTICS, INC.
Page 8 - PROTAGONIST THERAPEUTICS, INC.
Page 9 - PROTAGONIST THERAPEUTICS, INC.
Page 10 - PROTAGONIST THERAPEUTICS, INC.
Page 11 - PROTAGONIST THERAPEUTICS, INC.
Page 12 - PROTAGONIST THERAPEUTICS, INC.
Page 13 - PROTAGONIST THERAPEUTICS, INC.
Page 14 - PROTAGONIST THERAPEUTICS, INC.
Page 15 - PROTAGONIST THERAPEUTICS, INC.
Page 16 - PROTAGONIST THERAPEUTICS, INC.
Page 17 - PROTAGONIST THERAPEUTICS, INC.
Page 18 - PROTAGONIST THERAPEUTICS, INC.
Page 19 - PROTAGONIST THERAPEUTICS, INC.
Page 20 - PROTAGONIST THERAPEUTICS, INC.
Page 21 - PROTAGONIST THERAPEUTICS, INC.
Page 22 - PROTAGONIST THERAPEUTICS, INC.
Page 23 - PROTAGONIST THERAPEUTICS, INC.
Page 24 - PROTAGONIST THERAPEUTICS, INC.
Page 25 - PROTAGONIST THERAPEUTICS, INC.
Page 26 - PROTAGONIST THERAPEUTICS, INC.
Page 27 - ITEM 2.MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Page 28 - N/A
Page 29 - Janssen License and Collaboration Agreement
Page 30 - Research and Development Expenses
Page 31 - General and Administrative Expenses
Page 32 - Results of Operations
Page 33 - General and Administrative Expenses
Page 34 - Research and Development Expenses
Page 35 - N/A
Page 36 - Cash Flows from Operating Activities
Page 37 - Cash Flows from Financing Activities
Page 38 - ITEM 4.CONTROLS AND PROCEDURES
Page 39 - Risks Related to Our Financial Position and Capital Requirements
Page 40 - N/A
Page 41 - We will require substantial additional funding, which may not be available to us on acceptable terms
Page 42 - N/A
Page 43 - Raising additional capital may cause dilution to our existing stockholders, restrict our operations
Page 44 - N/A
Page 45 - If Janssen does not elect to continue the development of PTG-200 through an Opt-In Election, our bus
Page 46 - The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time co
Page 47 - Clinical development is a lengthy and expensive process with an uncertain outcome, and results of ea
Page 48 - Enrollment and retention of patients in clinical trials is an expensive and time-consuming process a
Page 49 - All of our peptide-based product candidates other than PTG-100, PTG-200 and PTG-300 are in research
Page 50 - Our proprietary peptide platform may not result in any products of commercial value.
Page 51 - If there are any safety or efficacy results that cause the benefit-risk profile of PTG-200 to become
Page 52 - We face a variety of manufacturing risks and rely on third parties to manufacture our drug substance
Page 53 - We may fail to obtain orphan drug designations from the FDA for our product candidates, as applicabl
Page 54 - We may not be successful in obtaining or maintaining development and commercialization collaboration
Page 55 - We face significant competition from other biotechnology and pharmaceutical companies, and our opera
Page 56 - N/A
Page 57 - We have not yet negotiated our agreement with Janssen specifying all of the terms of our Co-Detailin
Page 58 - Even if our peptide-based product candidates receive marketing approval, they may fail to achieve ma
Page 59 - Even if we obtain and maintain approval for any of our product candidates from the FDA, we may never
Page 60 - N/A
Page 61 - Recently enacted and future legislation may increase the difficulty and cost for us to obtain market
Page 62 - N/A
Page 63 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 64 - Our future success depends on our ability to retain our executive officers and to attract, retain an
Page 65 - Significant disruptions of information technology systems or breaches of data security could adverse
Page 66 - If we fail to comply with environmental, health and safety laws and regulations, we could become sub
Page 67 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 68 - We currently conduct, and intend to continue to conduct, a substantial portion of the clinical trial
Page 69 - The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to
Page 70 - Risks Related to Our Intellectual Property
Page 71 - N/A
Page 72 - We may be involved in lawsuits to protect or enforce our intellectual property, which could be expen
Page 73 - Any issued patents covering our product candidates, including any patent that may issue as a result
Page 74 - Competitors could enter the market with generic versions of our product candidates, which may result
Page 75 - N/A
Page 76 - We may not identify relevant third party patents or may incorrectly interpret the relevance, scope o
Page 77 - Obtaining and maintaining patent protection depends on compliance with various procedural, document
Page 78 - Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecut
Page 79 - We may be subject to claims that our employees, consultants or independent contractors have wrongful
Page 80 - We have not yet registered trademarks for a commercial trade name for our product candidates and fai
Page 81 - Risks Related to Ownership of our Common Stock
Page 82 - N/A
Page 83 - Volatility in our share price could subject us to securities class action litigation.*
Page 84 - We have identified material weaknesses in our internal control over financial reporting and may iden
Page 85 - We are an emerging growth company and as a result of the reduced disclosure and governance requireme
Page 86 - Future sales of our common stock may depress our share price.*
Page 87 - Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 88 - Nasdaq may delist our securities from its exchange, which could limit investors ability to make tran
Page 89 - Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future
Page 90 - Our board of directors has certain characteristics which may delay or prevent a change of our manage
Page 91 - Provisions under Delaware law and California law could make an acquisition of our company more diffi
Page 92 - ITEM 3.DEFAULTS UPON SENIOR SECURITIES
Page 93 - EXHIBIT INDEX
Page 94 - N/A
Page 95 - SIGNATURES
Subdocument 2 - EX-10.2 - EX-10.2
Page 1 - Exhibit 10.2
Page 2 - N/A
Page 3 - May 21, 2018.
Subdocument 3 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 4 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 5 - EX-32.1 - EX-32.1
Page 1 - N/A
XBRL Item - EX-101.INS - EX-101.INS (What's this?)
XBRL Item - EX-101.SCH - EX-101.SCH (What's this?)
XBRL Item - EX-101.CAL - EX-101.CAL (What's this?)
XBRL Item - EX-101.DEF - EX-101.DEF (What's this?)
XBRL Item - EX-101.LAB - EX-101.LAB (What's this?)
XBRL Item - EX-101.PRE - EX-101.PRE (What's this?)
XBRL Viewer